Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic!

Int J Immunopathol Pharmacol. 2020 Jan-Dec:34:2058738420941754. doi: 10.1177/2058738420941754.

Abstract

Aim of this communication is to remind clinical professionals to be aware of ototoxic side effects of several specific drugs proposed for the treatment of the new virus SARS-CoV-2 (Covid-19). In particular, chloroquine and hydroxychloroquine, azithromycin, as well as antiviral drugs such as remdesivir, favipiravir and lopinavir can all present potential ototoxic side effects. The data in the literature do not offer specific information on their potential synergetic effects nor on their interactions.

Keywords: SARS-CoV-2 (Covid-19) pandemic; chloroquine; favipiravir; hydroxychloroquine; lopinavir; ototoxicity; remdesivir.

Publication types

  • Letter

MeSH terms

  • Antimalarials / adverse effects
  • Antimalarials / therapeutic use
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use
  • Azithromycin / adverse effects
  • Azithromycin / therapeutic use
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / complications*
  • Coronavirus Infections / drug therapy
  • Drug Monitoring*
  • Hearing Disorders / chemically induced*
  • Hearing Disorders / complications*
  • Hearing Disorders / therapy
  • Hearing Tests
  • Humans
  • Ototoxicity*
  • Pandemics
  • Pneumonia, Viral / complications*

Substances

  • Antimalarials
  • Antiviral Agents
  • Azithromycin